TMThomas R. Malek

Thomas R. Malek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas R. Malek has a total of 117 co-authors. Here are the top co-authors by number of shared publications:

  • Aixin Yu

    Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA

    16 shared publications
  • Allison L. Bayer

    Division of Endocrinology, Diabetes, and Metabolism Department of Medicine University of Miami Miller School of Medicine Miami FL

    6 shared publications
  • Rosmely Hernandez

    Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA

    6 shared publications
  • Alicia Santos Savio

    Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA

    5 shared publications
  • Dennis Adeegbe

    Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL 33136

    5 shared publications
  • Janika Põder

    Department of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA

    5 shared publications

Latest Publications

  • Open Access

    IL-2/CD25 acts within the tumor microenvironment to reprogram tumor-specific cytotoxic CD8 + T cells while restraining regulatory T-cell accumulation

    by Kathryn M LaPorte, Janika Põder, Daria Ivanova, Molly Dalzell, Paolo Serafini, Alejandro V Villarino, Thomas R Malek

    Background: Targeting the high-affinity interleukin-2 receptor (IL-2R) on CD8 + T effector cells elicits potent antitumor responses that are augmented when co-administered with programmed cell death protein 1 (PD-1) blockade. Methods: Using the mouse IL-2/CD25 fusion protein (mIL-2/CD25) at a high dose (HD) and anti-PD-1 checkpoint blockade, with the CT26 and MC38 colon carcinomas as models, the current study investigated how antitumor responses occurred when regulatory T cells (Tregs) are also a target of HD mIL-2/CD25. Single-cell RNA sequencing (scRNA-seq) and T-cell receptor (TCR) repertoire analysis of tumor-associated immune cells were used to identify how combination therapy reshaped the tumor microenvironment (TME). These data were cross-referenced with published datasets to (1) corroborate TCR specificity and (2) identify how CD8 + T-cell differentiation is affected by different IL-2/PD-1 strategies. Results: Here, we show that effective antitumor immunity by the combination therapy is a result of HD mIL-2/CD25-dependent reprogramming of CD8 + tumor-specific T cells that increases their function and supports their expansion within the TME, the latter also shaped by PD-1 blockade. This therapy supports antitumor responses by chemokines and inflammatory cytokines that selectively favor the migration of CD8 + T cells but not Tregs deep within the tumor. After HD mIL-2/CD25 treatment, Tregs within the TME showed impaired downstream IL-2R signaling, reflected by failed upregulation of forkhead box P3 and CD25, impaired development into effector Tregs, and enhanced cell death, the latter which likely offsets Treg proliferation. Many similarities were noted after direct comparison of these scRNA-seq findings with another study where IL-2 activity was targeted to PD-1 + CD8 + T cells. Notably, HD mIL-2/CD25 and anti-PD-1 combination promotes effector and ‘stem-like’ CD8 + T-cell subsets, perhaps even to a greater extent than the PD-1-targeted IL-2 strategy. Conclusions: The efficient differentiation of exhausted CD8 + T cells into highly functional cells and the resulting potent antitumor responses by HD mIL-2/CD25 plus anti-PD-1 suggest that this approach may augment durable response rates more than currently achieved with checkpoint blockade monotherapy.

  • Open Access

    The transcription factor SREBP2 supports the activation and homeostasis of CD4+ Foxp3+ regulatory T cells

    by Acacia N Shouse, Alejandro V Villarino, Thomas R Malek

    Periodic activation of regulatory T cells (Tregs) is necessary to restrict autoreactive T cells and maintain immune homeostasis. IL-2–STAT5 signaling instructs several metabolic processes underlying Treg activation, including the mevalonate pathway, which is crucial for optimal Treg responses. However, direct links between IL-2–STAT5, mevalonate, and Treg function have yet to be established. To explore this relationship, we deleted sterol regulatory binding element protein 2 (Srebp2), a critical mediator of mevalonate metabolism, selectively in Tregs. Here, we show that when Srebp2-deficient Tregs are placed under physiological stress by competing with wild-type Tregs, the former exhibit impaired proliferation, survival, and activation. RNA sequencing of Tregs in this competitive setting demonstrate that Srebp2 contributes to pathways controlling IL-2R signaling, cholesterol homeostasis, activities associated with the mevalonate pathway, and expression of genes associated with activated Tregs. These findings link Srebp2, the IL-2R, and the mevalonate pathways for efficient Treg homeostasis and activation. These effects, however, require a competitive setting, as mice with only Srebp2-deficient Tregs were outwardly normal with respect to their development, homeostasis, metabolic activity, and function. Thus, Srebp2 is necessary to optimally tune Treg homeostasis and activation, but sufficient redundancy exists to compensate for the lack of Srebp2 to maintain Treg development and function in the absence of physiological stress.

  • Open Access

    Durable control of autoimmunity requires sustained stimulation of regulatory T cells

    by Janika Põder, Aixin Yu, Ying Ding, Céline Albalaa, David Klatzmann, Alejandro V. Villarino, Paolo Serafini, Thomas R. Malek


  • Open Access

    BLIMP-1 and CEACAM1 cooperatively regulate human Treg homeostasis and function to control xenogeneic GVHD

    by Ying Ding, Aixin Yu, Milos Vujanac, Sabrina N. Copsel, Alejandro Moro, Luis Nivelo, Molly Dalzell, Nicolas Tchitchek, Michelle Rosenzwajg, Alejandro V. Villarino, et al.

    Regulatory T cells (Tregs) are essential for peripheral tolerance and depend on TCR and IL-2 receptor (IL-2R) signaling for their homeostasis and function. In mice, IL-2–dependent B-lymphocyte-induced maturation protein 1 (BLIMP-1) contributes to Treg homeostasis. BLIMP-1 is a major transcriptional hub in human Tregs, but its mechanisms of action remain undefined. Here, using CRISPR/Cas9 ablation, we show that BLIMP-1 limits human Treg proliferation but supports IL-10, cytotoxic T lymphocyte-associated protein 4, several immune checkpoints including carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), and Treg functional activity. BLIMP-1 restrains Treg expansion to IL-2 by downregulating CD25 and IL-2R signaling, and by enhancing CEACAM1 expression, which in turn inhibits responsiveness to CD3/CD28 signaling and activation of mTOR. Prolonged IL-2R signaling optimizes BLIMP-1 expression, supporting chromosomal opening of CEACAM1 to increased CEACAM1 expression through STAT5- and BLIMP-1–driven enhancers. Correspondingly, CEACAM1 is highly induced on Tregs from patients with autoimmune disease undergoing low-dose IL-2 therapy, and these Tregs showed reduced proliferation. A humanized mouse model of xenogeneic graft-versus-host disease demonstrates that BLIMP-1 normally promotes, while CEACAM1 restrains, Treg suppressive activity. Collectively, our findings reveal that BLIMP-1 and CEACAM1 function in an IL-2–dependent feedback loop to restrain Treg proliferation and affect suppressive function. CEACAM1 also acts as a highly selective biomarker of IL-2R signaling in human T cells.


  • Open Access

    The Role of Viruses in the Glioma Tumor Microenvironment: Immunosuppressors or Primers for Anti-Tumor Immunity?

    by Anna J. Hudson, Jay Chandar, Muhammet Enes Gurses, Thomas Malek, Ashish H. Shah

    The WHO estimates that nearly 10–15% of cancers have a known viral etiology, although this number is likely an underestimate. In glioblastoma (GBM), the most common primary brain malignancy, viral associations have been proposed and investigated without a definitive etiology. Viral–host interactions are known to alter cellular growth and stem cell programming, as well as modulate innate immune signaling. However, in GBM, the multifaceted role of endogenous or exogenous viral expression remains unclear. Here, we provide a review of common viral associations in GBM and discuss how these viruses modulate intrinsic cellular processes to enhance anti-viral immune response or suppress anti-tumor immunity.


  • Open Access

    Growth of human regulatory CD4+ T cells is more tightly controlled than effector T cells due to distinctive molecular programming

    by Alejandro Moro, Aixin Yu, Luis Nivelo, Zhen Gao, Yuguang Ban, Alejandro V. Villarino, Thomas R. Malek


  • Open Access

    Interleukin-2 receptor signaling acts as a checkpoint that influences the distribution of regulatory T cell subsets

    by Acacia N. Shouse, Alejandro V. Villarino, Thomas R. Malek


  • Top Cited Papers

    Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer

    by Acacia N. Shouse, Kathryn M. LaPorte, Thomas R. Malek


  • Open Access

    Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells

    by Kathryn M LaPorte, Rosmely Hernandez, Alicia Santos Savio, Thomas R Malek

    Background: Development of interleukin (IL)-2-dependent antitumor responses focus on targeting the intermediate affinity IL-2R to stimulate memory-phenotypic CD8+ T and natural killer (NK) cells while minimizing regulatory T cell (Treg) expansion. However, this approach may not effectively engage tumor-specific T effector cells. Since tumor-antigen specific T cells upregulate the high-affinity IL-2R, we tested an IL-2 biologic, mouse IL-2/CD25, with selectivity toward the high-affinity IL-2R to support antitumor responses to tumors that vary in their immunogenicity. Methods: Mice were first implanted with either CT26, MC38, B16.F10, or 4T1 and after a tumor mass developed, they were treated with high-dose (HD) mouse (m)IL-2/CD25 alone or in combination with anti-programmed cell death protein-1 (PD-1) checkpoint blockade. Tumor growth was monitored and in parallel the immune signature in the tumor microenvironment (TME) was determined by a combination of multiparameter flow cytometry, functional assays, and enumeration of tumor-reactive T cells. Results: We show that HD mIL-2/CD25, which preferentially stimulates the high-affinity IL-2R, but not IL-2/anti-IL-2 complexes with preferential activity toward the intermediate-affinity IL-2R, supports vigorous antitumor responses to immunogenic tumors as a monotherapy that were enhanced when combined with anti-PD-1. Treatment of CT26-bearing mice with HD mIL-2/CD25 led to a high CD8+:Treg ratio in the TME, increased frequency and function of tumor-specific CD8+ T effector cells with a less exhausted phenotype, and antitumor memory responses. Conclusions: Targeting the high-affinity IL-2R on tumor-specific T cells with HD mIL-2/CD25 alone or with PD-1 blockade supports antitumor responses, where the resulting memory response may afford long-term protection against tumor re-emergence.


  • Open Access

    Immunotherapy With Low-Dose IL-2/CD25 Prevents β-Cell Dysfunction and Dysglycemia in Prediabetic NOD Mice

    by Farhan M. Qureshi, Julia K. Panzer, Janika Põder, Thomas R. Malek, Alejandro Caicedo

    Low-dose IL-2 is a promising immunotherapy in clinical trials for treating type 1 diabetes. A new IL-2 analog, IL-2/CD25 fusion protein, has been shown to more efficiently delay or prevent diabetes in NOD mice by expanding the population of activated regulatory T cells. This therapy is intended for use before clinical diagnosis, in the early stages of type 1 diabetes progression. During this prediabetic period, there is a chronic decline in β-cell function that has long-term implications for disease pathogenesis. Yet, to date, the effects of IL-2/CD25 on β-cell function have not been evaluated. In this study, we treated prediabetic NOD mice with low-dose mouse IL-2/CD25 over 5 weeks and determined its impact on β-cell function. This treatment limited the progressive impairment of glucose tolerance and insulin secretion typical of the later stages of prediabetes. Intracellular Ca2+ responses to glucose in β-cells became more robust and synchronous, indicating that changing the local immune cell infiltrate with IL-2/CD25 preserved β-cell function even after treatment cessation. Our study thus provides mechanistic insight and serves as a steppingstone for future research using low-dose IL-2/CD25 immunotherapy in patients. Article Highlights: Immunotherapies such as IL-2/CD25 are known to prevent or delay diabetes. However, their impact on individual β-cell function is not yet understood. Female NOD mice progress from stage 1 to 2 pre–type 1 diabetes between 12 and 17 weeks. Treatment with mouse IL-2 (mIL-2)/CD25 prevents this progression even after treatment cessation. Individual β-cell function (measured via intracellular Ca2+ responses to glucose) declines during the pathogenesis of type 1 diabetes. Treatment with mIL-2/CD25 therapy limits β-cell dysfunction, and function continues to improve after treatment cessation. Insulin secretion is improved with mIL-2/CD25 therapy.